Metropolis Healthcare Limited has scheduled a series of meetings with analysts and institutional investors for June 2026. The company will engage with Morgan Stanley India and Choice Broking to discuss business performance based on publicly available information.

Meeting Schedule

The interactions are structured as One to One and Group Meetings. The schedule is subject to change due to exigencies on the part of the participants, host, or the company.

Disclosure Compliance

The intimation was submitted pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that no unpublished price sensitive information (UPSI) is intended to be discussed during these interactions. The information is also available on the company's website.

Metropolis Healthcare Limited has announced its financial results for the quarter and year ended March 31, 2026. The company reported a strong performance across key metrics, driven by robust organic growth and successful integration of acquisitions. For the full year FY26, the MHL Group revenue stood at INR 1,646 crores, reflecting a year-on-year growth of 23.6%. The EBITDA margin for the year was 24.4%, while the Profit After Tax (PAT) stood at INR 191 crores, growing by 31% year-on-year. The Board has recommended an interim dividend of INR 1 per share.

Financial Performance

The company delivered solid results in the fourth quarter as well. Q4FY26 revenue stood at INR 425 crores, a 23% increase year-on-year, with an EBITDA margin of 25.4%. On an organic basis, revenue grew by 14.7% in Q4, driven by a 9.3% increase in patient volume and a 5% improvement in realizations. The Board has recommended an interim dividend of INR 1 per share.

Operational Highlights

Management highlighted that the quality of growth remains strong, supported by patient volume growth and better mix. The network expanded to over 5,000 collection centers and 212 labs. The center-to-lab ratio improved to 24:1, with a target to reach 35:1 over the next three years. Productivity initiatives, including lab platform upgrades and vendor consolidation, have started yielding benefits, contributing to margin expansion.

Strategic Outlook

Looking ahead, Metropolis Healthcare provided guidance for a revenue CAGR of 14% to 15% over the next three years. The company aims to achieve a sustainable group EBITDA margin of 27% to 28% during this period. Key growth drivers include volume expansion, price realization, and strategic acquisitions. The company also plans to establish 100 mini hubs offering pathology and basic radiology services to enhance its service offerings.